What Happened
- The 2026 AMR Benchmark report by the Access to Medicine Foundation evaluated 25 pharmaceutical companies — 7 large research-based firms, 10 generic manufacturers, and 8 small-to-medium enterprises — and found that "drug resistance is outpacing industry-wide efforts."
- Large research-based pharmaceutical companies experienced a 35% decline in their antimicrobial drug development pipelines, even as seven late-stage projects with genuine innovation potential were identified.
- Two notable drug candidates emerged: GSK's gepotidacin (first new oral antibiotic class for urinary tract infections in ~30 years) and Innoviva's zoliflodacin (for gonorrhea) — both representing the first new oral treatments in decades for their respective conditions.
- Gonorrhea affects approximately 82 million people annually and is now resistant to nearly every antibiotic class; UTIs affect 150 million people per year, with 50-60% of women experiencing one in their lifetime.
- Critical access gaps remain: five major pharmaceutical manufacturers register their pediatric antimicrobial formulations in only 50-70% of the Low- and Middle-Income Countries (LMICs) where they sell other antimicrobials; 17 sub-Saharan African nations had no child-friendly formulations registered at all.
- The Foundation concluded that pharmaceutical companies alone cannot solve AMR — coordinated action across healthcare, agriculture, environment, and government sectors through a One Health framework is essential.
Static Topic Bridges
Antimicrobial Resistance (AMR) — Mechanisms and Global Burden
Antimicrobial resistance occurs when bacteria, viruses, fungi, or parasites evolve mechanisms to survive exposure to medicines that would ordinarily kill them. AMR is a natural evolutionary process accelerated by overuse and misuse of antimicrobials in human medicine, animal husbandry, and agriculture.
- Key resistance mechanisms in bacteria: Beta-lactamase enzyme production (breaks down penicillin/cephalosporins); efflux pumps (expel antibiotics from the cell); altered target sites (prevents antibiotic binding); biofilm formation; horizontal gene transfer via plasmids (spreads resistance between bacteria rapidly)
- Global mortality: Over 1 million deaths directly attributable to drug-resistant infections annually; AMR contributes to over 4 million deaths; projected to reach ~1.9 million direct deaths and 8+ million associated deaths by 2050 (O'Neill Report, 2016)
- India-specific context: India is among the countries with the highest burden of drug-resistant tuberculosis (DR-TB), extensively drug-resistant (XDR) typhoid, carbapenem-resistant gram-negative bacteria, and methicillin-resistant Staphylococcus aureus (MRSA)
- ESKAPE pathogens: WHO's priority pathogen list (2017) of most dangerous drug-resistant organisms — Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species
Connection to this news: The 35% pipeline decline documented by the AMR Benchmark 2026 means fewer new antibiotics are in development precisely as existing ones face mounting resistance — a classic supply-demand mismatch with lethal consequences.
One Health Approach and WHO Global Action Plan on AMR
The One Health framework recognises that human health, animal health, and environmental health are deeply interconnected and must be addressed together to tackle complex challenges like AMR. AMR pathogens move freely between humans, animals, food, water, and soil.
- WHO Global Action Plan on AMR (GAP-AMR): Adopted by the World Health Assembly in May 2015; five strategic objectives: (1) awareness and education, (2) surveillance and research, (3) infection prevention and control, (4) optimising antimicrobial use, (5) investment in R&D
- 2026 GAP-AMR Update: Requested by the 79th UN General Assembly High-Level Meeting (2024) on AMR; Quadripartite (WHO, FAO, UNEP, WOAH) mandated to update the plan for adoption by May 2026 — the Access to Medicine Foundation report feeds into this policy window
- India's National Action Plan (NAP) on AMR: Released April 2017 by Union Ministry of Health and Family Welfare; aligns with WHO's five GAP objectives; targets human, animal, agriculture, fisheries, and environmental sectors; mandates sub-national action plans for states
- Key challenge: Agricultural use of antibiotics — particularly as growth promoters in livestock — is a major driver of resistance; India is one of the world's largest consumers of veterinary antibiotics; the Drug Controller General of India (DCGI) has progressively restricted veterinary antibiotic use
Connection to this news: The AMR Benchmark 2026 report's conclusion that "coordinated action across sectors" is essential directly echoes the One Health mandate — companies alone developing new drugs is insufficient if overuse in agriculture and inadequate infection control continue generating resistance faster than new drugs can be developed.
Drug Development Pipeline and Market Failure
The development of new antibiotics faces a structural market failure: antibiotics are used for short courses (days to weeks), priced modestly, and doctors are actively encouraged to preserve new drugs by using them sparingly — all of which make antibiotics commercially unattractive despite their public health necessity.
- Average cost to develop a new antibiotic: approximately $1.5 billion USD, with a decade-long timeline
- Revenue from a new antibiotic: often less than $50 million/year in the first years post-approval (compared to $2-3 billion/year for a blockbuster cancer drug or diabetes drug)
- Most major pharmaceutical companies exited antibiotic R&D between 2000–2018: Pfizer, Eli Lilly, Novartis, AstraZeneca, Sanofi all withdrew or scaled back significantly
- Push incentives (government-funded R&D grants) vs. Pull incentives (market-entry rewards for successful new antibiotics): The UK and US have experimented with subscription-based "Netflix model" for antibiotics (pay companies annually regardless of sales volume)
- GARDP (Global Antibiotic Research and Development Partnership): WHO-linked initiative providing non-profit pipeline support for antibiotics targeting critical pathogens; zoliflodacin (gonorrhea) was co-developed by GARDP and Innoviva
- India's iDEX and DBT (Department of Biotechnology) have limited AMR-specific R&D initiatives; the need for domestic antibiotic innovation is growing
Connection to this news: The 35% pipeline decline among large pharma is the direct consequence of this market failure — a structural problem requiring policy solutions (pull incentives, subscription models, international treaties on R&D investment) rather than company-by-company initiative.
India's AMR Burden and Stewardship Obligations
India faces a particularly acute AMR challenge due to: high antibiotic consumption (both appropriate and inappropriate), over-the-counter availability of antibiotics without prescription (technically illegal but poorly enforced), dense population enabling rapid pathogen transmission, and a large burden of infectious diseases requiring treatment.
- India has approximately 26,500 DR-TB cases annually (among the highest globally); XDR-TB cases are rising
- Antibiotic stewardship: The practice of coordinating prescribing to minimise unnecessary use; India's National Centre for Disease Control (NCDC) runs the AMR Surveillance Network; Hospital Infection Control Committees are mandated in NABH-accredited hospitals
- Schedule H1 drugs: A 2013 amendment to the Drugs and Cosmetics Act, 1940 created Schedule H1 — a category of antibiotics and other critical medicines requiring written prescriptions, pharmacist record-keeping, and restricted sale; includes fluoroquinolones, cephalosporins, carbapenems
- India's Antibiotic Stewardship Program (ICMR-ASP): guidelines for prescribing antibiotics in ICUs and clinical settings, developed by the Indian Council of Medical Research (ICMR)
- The FSSAI (Food Safety and Standards Authority of India) regulates maximum antibiotic residue limits in food of animal origin — a key One Health intervention
Connection to this news: The AMR Benchmark 2026 finding that companies are "starting to take ownership" is encouraging but insufficient. India-specific policy tools — Schedule H1, ICMR stewardship, FSSAI residue limits — represent the stewardship side of a two-sided problem where new drug development is the other.
Key Facts & Data
- AMR direct mortality: over 1 million deaths/year; contributing to 4+ million deaths/year (2026)
- Projected deaths by 2050: ~1.9 million direct; 8+ million associated (O'Neill Report baseline)
- AMR Benchmark 2026: evaluated 25 companies (7 large research-based, 10 generic, 8 SMEs)
- Large pharma antimicrobial pipeline decline: 35% (AMR Benchmark 2026)
- GSK's gepotidacin: first new oral antibiotic class for UTIs in ~30 years
- Innoviva's zoliflodacin: first new oral gonorrhea treatment in decades; developed with GARDP
- Gonorrhea global burden: ~82 million cases/year; UTI burden: ~150 million cases/year
- WHO Priority Pathogen List (2017): ESKAPE organisms — highest priority for new antibiotic development
- India NAP-AMR: released April 2017 by Ministry of Health and Family Welfare
- WHO GAP-AMR: adopted 2015; update mandated by 2026 for adoption by World Health Assembly (May 2026)
- Schedule H1 (Drugs and Cosmetics Act): created 2013; requires prescription + pharmacist records for critical antibiotics
- GARDP: Global Antibiotic Research and Development Partnership; WHO-linked non-profit AMR R&D